MEENAKSHI HEGDE to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications MEENAKSHI HEGDE has written about Xenograft Model Antitumor Assays.
Connection Strength
0.239
-
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101.
Score: 0.087
-
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 05; 26(5):720-731.
Score: 0.035
-
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021 01; 35(1):75-89.
Score: 0.034
-
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018 03 27; 20(4):506-518.
Score: 0.030
-
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018 01 15; 78(2):489-500.
Score: 0.029
-
T cells redirected to interleukin-13Ra2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ra1. Cytotherapy. 2014 Aug; 16(8):1121-31.
Score: 0.023